| In
a randomized placebo controlled double blind trial, 62 patients of pulmonary TB
were given either OptiLiv or placebo during the first 45 days of intensive phase
ATT. In addition, 8 patients already on ATT having drug induced jaundice were
also randomized and added to the above schedule of study in a dose of one capsule
twice a day but without any ATT. Changes in Serum Bilirubin, SGOT, SGPT and Alkaline
Phosphatase were negligible in OptiLiv supplemented groups, as compared to the
placebo group. Further, a significant rise in hemoglobin was also seen in the
OptiLiv treated group. In cases with established jaundice due to ATT, faster recovery
was seen in patients on OptiLiv treatment. With OPTILIV all patients had marked
feeling of well-being, improved appetite and weight gain and their bowel movements
became regular with well formed stools. This study thus
brings forth clearly the benefit of adding OptiLiv capsules as an integral part
of intensive phase ATT in order to prevent overt and incipient hepatotoxicity
and thus minimize the chances of treatment default and discontinuation, which
is a common cause for development of resistance to standard ATT.
Singh,
V.K. (2000), J.K. Practitioner (2000), 7 (4) : 289-292). Forty
adult patients of either sex and between 14 to 50 years of age suffering from
acute viral hepatitis were randomized. OptiLiv capsules or placebo were given
in 1 capsule b.d. dose for 15 days. Treatment with OptiLiv was associated with
significantly less (P<0.05) loss in body weight and rapid (P<0.05) clinical
and bio-chemical recovery, as compared to placebo. No relapse was observed in
OptiLiv group.
Biswas,
et al (1998), AIIMS, New Delhi, Paper was presented at XIIIthinternational Congress
of Pharmacology, 26-31 July, 1998, Munchen, Germany.
Clinical
Trial of OptiLiv was conducted in healthy male volunteers (age 20-40 years) as
per the terms of Helsinki declaration. Safety and tolerability of the formulation
was well established with no adverse effect on clinical or biochemical parameters.
Improvement was seen in hepatic and renal function values as they declined to
the lower limits of normal, from the higher range thereby signifying improved
and efficient hepatic and renal function. This was reflected in improvement of
subjective parameters in a majority of the volunteers who reported better appetite
and bowel evacuation. Significant anti-hypercholesterolaemic effect was noted
in individuals in whom Serum cholesterol values were > 220 mg. These effects
along with the high safety and tolerability profile of OptiLiv coupled with its
convenient dosage schedule make it an ideal herbal Hepatoprotective, Hepatogenic
and Hepatic tonic for use in liver dysfunction of varied aetiology. Mathur,
AK et. al.(1998). Paper presented at Annual APPI Conference, Imphal, Dec'98. |
